The CLL-IPI adopts 5 variables: TP53 status (deleted or mutated), IGHV status, β2-microglobulin, clinical stage Binet B/C or Rai I-IV, and age > 65 years. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.